MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Treatment

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal

Carcinogenesis 2018 April [Link] Schelch K et.al Abstract Malignant pleural mesothelioma (MPM), an aggressive malignancy affecting pleural surfaces, occurs in three main histological subtypes. The epithelioid and sarcomatoid subtypes are characterized by cuboid and fibroblastoid cells, respectively. The biphasic subtype contains a mixture of both. The sarcomatoid subtype expresses markers of epithelial-mesenchymal transition (EMT) and […]

Comments Off on FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal

Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification

Annals of Surgical Oncology 2018 April 3 [Epub ahead of print] [Link] Takuwa T, Hashimoto M, Kuroda A, Nakamura A, Nakamichi T, Fukuda A, Matsumoto S, Kondo N, Hasegawa S Abstract INTRODUCTION: The change in TNM classification of malignant pleural mesothelioma (MPM) between the seventh and eighth edition classifications has resulted in the downstaging of […]

Comments Off on Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma

JCI Insight 2018 April 5 [Epub ahead of print] [Link] Lee HS et. al. Asbstract We generated a comprehensive atlas of the immunologic cellular networks within human malignant pleural mesothelioma (MPM) using mass cytometry. Data-driven analyses of these high-resolution single-cell data identified 2 distinct immunologic subtypes of MPM with vastly different cellular composition, activation states, […]

Comments Off on Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma

Podoplanin – an emerging cancer biomarker and therapeutic target

Cancer Science 2018 March 25 [Epub ahead of print] [Link] Krishnan H et. al. Abstract Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts (CAFs), and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition (EMT), migration, invasion, metastasis, […]

Comments Off on Podoplanin – an emerging cancer biomarker and therapeutic target

Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma

Journal of Cellular and Molecular Medicine 2018 March 24 [Epub ahead of print] [Link] Hsu PC, et. al. Abstract Although tumour PD-L1 (CD274) expression had been used as a predictive biomarker in checkpoint immunotherapy targeting the PD1/PD-L1 axis in various cancers, the regulation of PD-L1 (CD274) expression is unclear. Yes-associated protein (YAP), an important oncogenic […]

Comments Off on Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications

Journal of the National Cancer Institute 2018 March 21 [Epub ahead of print] [Link] Barash U Abstract BACKGROUND: Mammalian cells express a single functional heparanase, an endoglycosidase that cleaves heparan sulfate and thereby promotes tumor metastasis, angiogenesis, and inflammation. Malignant mesothelioma is highly aggressive and has a poor prognosis because of the lack of markers […]

Comments Off on Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

European Respiratory Review 2018 March [Print 2018 March 31] Link] Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C Abstract Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have […]

Comments Off on Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Post-irradiation pericardial malignant mesothelioma with deletion of p16: a case report

Cancer and Biology Medicine 2018 February [Link] Naeini YB, Arcega R, Hirschowitz S, Rao N, Xu H Abstract Malignant mesotheliomas are rather uncommon neoplasms associated primarily with asbestos exposure; however, they may also arise as second primary malignancies after radiation therapy, with a latency period of 15-25 years. Numerous studies have reported an association between […]

Comments Off on Post-irradiation pericardial malignant mesothelioma with deletion of p16: a case report

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Frontiers in Oncology 2018 Februrary [Link] Oehl K et. al. Abstract Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can […]

Comments Off on Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma

The European Respiratory Journal [Epub ahead of print] [Link] Otsuki T et. al. Abstract Angiogenesis is a crucial factor in the progression of malignant pleural mesothelioma (MPM), and antiangiogenic strategies might be effective against MPM. Aminopeptidase N/CD13 (APN/CD13) promotes tumour angiogenesis and is associated with poor prognosis; however, its clinical significance in MPM remains unclear.In […]

Comments Off on Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma